SIDE EFFECTS
Gastrointestinal System: Gastrointestinal symptoms
occur frequently and have included nausea or vomiting, anorexia,
diarrhea, weight loss, epigastric and abdominal pain, and
constipation.
Hemopoietic System: Hemopoietic complications
associated with the administration of methsuximide have
included eosinophilia, leukopenia, monocytosis, and pancytopenia
with or without bone marrow suppression.
Nervous System: Neurologic and sensory
reactions reported during therapy with methsuximide have
included drowsiness, ataxia or dizziness, irritability and
nervousness, headache, blurred vision, photophobia, hiccups,
and insomnia. Drowsiness, ataxia, and dizziness have been
the most frequent side effects noted. Psychologic abnormalities
have included confusion, instability, mental slowness, depression,
hypochondriacal behavior, and aggressiveness. There have
been rare reports of psychosis, suicidal behavior, and auditory
hallucinations.
Integumentary System: Dermatologic manifestations
which have occurred with the administration of methsuximide
have included urticaria, Stevens-Johnson syndrome, and pruritic
erythematous rashes.
Cardiovascular: Hyperemia.
Genitourinary system: Proteinuria, microscopic
hematuria
Body as a Whole: Periorbital edema.
DRUG INTERACTIONS
Since Celontin (methsuximide) may interact with concurrently
administered antiepileptic drugs, periodic serum level
determinations of these drugs may be necessary (eg methsuximide
may increase the plasma concentrations of phenytoin and
phenobarbital).
|
|
